Brenda Reynolds
Director/Board Member at iQur Ltd.
Profile
Brenda Elizabeth Reynolds is the founder of PowderMed Ltd.
(founded in 2004), Convergence Pharmaceuticals Ltd.
(founded in 2010), and Calchan Ltd.
(founded in 2011).
She held the title of Chief Operating Officer at PowderMed Ltd.
from 2004 to 2008.
Dr. Reynolds currently holds multiple non-executive director positions at iQur Ltd., D3tex Ltd., Adiga Life Sciences, Inc., BQR Consulting Ltd., and Pleco Therapeutics BV.
She is also the owner of Questrax Ltd.
Dr. Reynolds received an undergraduate degree from the University of Surrey.
Brenda Reynolds active positions
Companies | Position | Start |
---|---|---|
iQur Ltd.
iQur Ltd. BiotechnologyHealth Technology iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
Questrax Ltd. | Corporate Officer/Principal | 19/08/2010 |
D3tex Ltd. | Director/Board Member | - |
BQR Consulting Ltd. | Director/Board Member | - |
Pleco Therapeutics BV
Pleco Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans. | Director/Board Member | - |
Adiga Life Sciences, Inc.
Adiga Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Adiga Life Sciences, Inc. operates as a healthcare company that conducts medical researches. It develops technologies to control immune function in allergic and auto immune diseases. The company was founded on November 25, 2008 and is headquartered in Hamilton, Canada. | Director/Board Member | - |
Former positions of Brenda Reynolds
Companies | Position | End |
---|---|---|
PowderMed Ltd.
PowderMed Ltd. Pharmaceuticals: MajorHealth Technology PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom. | Founder | 23/10/2008 |
University of Birmingham Enterprise Ltd.
University of Birmingham Enterprise Ltd. Investment ManagersFinance University of Birmingham Enterprise Ltd (University of Birmingham Enterprise) is a venture capital subsidiary of University of Birmingham founded in 2008. The firm is headquartered in Birmingham, United Kingdom. | Private Equity Investor | - |
Calchan Ltd.
Calchan Ltd. BiotechnologyHealth Technology Calchan Ltd. operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain. The company was founded by Brenda Elizabeth Reynolds in 2011 and is headquartered in London, the United Kingdom. | Chief Executive Officer | - |
░░░ ░░░░░░░░░ ░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Training of Brenda Reynolds
University of Surrey | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
PFIZER, INC. | Health Technology |
Private companies | 19 |
---|---|
Powderject Pharmaceuticals Plc
Powderject Pharmaceuticals Plc Medical SpecialtiesHealth Technology Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK | Health Technology |
iQur Ltd.
iQur Ltd. BiotechnologyHealth Technology iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom. | Health Technology |
Altimmune UK Ltd.
Altimmune UK Ltd. BiotechnologyHealth Technology Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom. | Health Technology |
PowderMed Ltd.
PowderMed Ltd. Pharmaceuticals: MajorHealth Technology PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom. | Health Technology |
Questrax Ltd. | |
G.D. Searle & Co., Inc.
G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Process Industries |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
DC Biosciences Ltd.
DC Biosciences Ltd. BiotechnologyHealth Technology DC Biosciences Ltd. provides bioreagents and life science services. The firm’s products include cell extracts, fresh primary mammalian cells, recombinant proteins, steroid beads, fluorescent cell markers, and SILAC reagents. Its services include custom antibody service, custom antibody service, DNA cloning services, gene synthesis service, and protein expression, gene to stable cell line, mass spectrometry, quantitative proteomics, and peptide synthesis. The company was founded by Angus Lamond and Paul Ajuh in June 2006 and is headquartered in Dundee, the United Kingdom. | Health Technology |
Calchan Holdings Ltd.
Calchan Holdings Ltd. Pharmaceuticals: MajorHealth Technology Calchan Holdings Ltd. develops novel oral state-dependent calcium channel modulators for chronic pain. The company was founded on February 25, 2011 and is headquartered in London, the United Kingdom. | Health Technology |
Scotia Holdings Plc | Commercial Services |
D3tex Ltd. | |
Beecham Pharmaceuticals (UK) | |
BQR Consulting Ltd. | |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
The Institute of Directors (United Kingdom)
The Institute of Directors (United Kingdom) Miscellaneous Commercial ServicesCommercial Services The Institute of Directors (United Kingdom) is a community of passionate UK business leaders. The non-profit company is based in Birmingham, UK, and has subsidiaries in the United Kingdom. The British company provides professional training opportunities and access to essential help and resources for its members. The CEO of the company is Stephen Martin. | Commercial Services |
Calchan Ltd.
Calchan Ltd. BiotechnologyHealth Technology Calchan Ltd. operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain. The company was founded by Brenda Elizabeth Reynolds in 2011 and is headquartered in London, the United Kingdom. | Health Technology |
University of Birmingham Enterprise Ltd.
University of Birmingham Enterprise Ltd. Investment ManagersFinance University of Birmingham Enterprise Ltd (University of Birmingham Enterprise) is a venture capital subsidiary of University of Birmingham founded in 2008. The firm is headquartered in Birmingham, United Kingdom. | Finance |
Pleco Therapeutics BV
Pleco Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans. | Commercial Services |
Adiga Life Sciences, Inc.
Adiga Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Adiga Life Sciences, Inc. operates as a healthcare company that conducts medical researches. It develops technologies to control immune function in allergic and auto immune diseases. The company was founded on November 25, 2008 and is headquartered in Hamilton, Canada. | Health Technology |
- Stock Market
- Insiders
- Brenda Reynolds